Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY:PFE)

23.87 -0.99 (-3.98%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Pfizer's yield is high, and so too is its payout ratio. 
Via The Motley Fool
3 Hyped Up Stocks That Fall Short
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Intel, Nvidia, Twilio, Palo Alto Networks, Pfizer: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Intel continued its winning run amid news of new strategic investment, while Nvidia saw activity as traders geared up for its quarterly results due next week. 
Via Stocktwits
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
How Do Investors Really Feel About Pfizer?
 
Via Benzinga
These S&P500 stocks are the most active in today's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
These three businesses have been raising their payouts for at least 16 consecutive years. 
Via The Motley Fool
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns. 
Via The Motley Fool
Topics Earnings Intellectual Property
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
3 Long-Term Dividend Buys You Can Get for Under $50
Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors 
Via MarketBeat
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Pfizer beat expectations last quarter and it raised its guidance. 
Via The Motley Fool
Topics World Trade
Celcuity Expenses Jump 81 Percent
Via The Motley Fool
Cautious Start On Dalal Street As Traders Eye Expiry, WPI Inflation Data; Muthoot Hits Record High, Infosys Gains on Versent Deal
Markets watch for the Trump–Putin meeting tomorrow that could impact Russia–Ukraine peace talks. Analysts see 24,600 as a make-or-break level for Nifty ahead of weekly expiry volatility. 
Via Stocktwits
Topics Economy Government
Most active S&P500 stocks in Wednesday's session
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year.... 
Via StockStory
Topics Earnings
PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full... 
Via StockStory
Topics World Trade
The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call
Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance... 
Via StockStory
Topics Earnings
Trading Radar For August 13: Paytm, HUL, Cochin Shipyard, Karnataka Bank, And Jindal Steel Are On Stocks Watchlist
BPCL, Pfizer, Vishal Mega Mart, among others, are expected to post their quarterly earnings today. 
Via Stocktwits
Topics Economy Energy
Pfizer Raises Its Guidance And Analysts Up Their Targets - PFE Stock Looks Cheap
Pfizer, Inc. stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. 
Via Talk Markets
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued
According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 
Via Stocktwits
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.